Float Short %

9.31

Margin Of Safety %

Put/Call OI Ratio

0.03

EPS Next Q Diff

0.09

EPS Last/This Y

1.44

EPS This/Next Y

-0.9

Price

3.96

Target Price

5.67

Analyst Recom

2.57

Performance Q

9.39

Relative Volume

0.52

Beta

2.05

Ticker: FULC

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	FULC	4.03	0.17	0.61	19061
2024-12-20	FULC	4.36	0.17	0.10	19115
2024-12-23	FULC	4.68	0.03	0.04	15308
2024-12-24	FULC	4.55	0.04	0.11	15529
2024-12-26	FULC	4.84	0.04	0.02	15767
2024-12-27	FULC	4.8	0.04	0.00	15747
2024-12-30	FULC	4.68	0.04	0.08	15747
2024-12-31	FULC	4.7	0.04	0.04	15755
2025-01-02	FULC	4.85	0.04	0.00	15760
2025-01-03	FULC	5.09	0.04	0.00	15931
2025-01-06	FULC	4.93	0.04	0.00	15940
2025-01-07	FULC	4.88	0.04	0.00	15967
2025-01-08	FULC	4.47	0.04	0.00	16052
2025-01-09	FULC	4.48	0.04	0.00	16052
2025-01-10	FULC	4.37	0.04	0.00	16195
2025-01-13	FULC	4.18	0.04	0.20	16244
2025-01-14	FULC	4.05	0.04	0.00	16248
2025-01-15	FULC	4.1	0.04	0.00	16237
2025-01-16	FULC	3.98	0.04	0.00	16269
2025-01-17	FULC	3.97	0.03	0.12	16246
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	FULC	4.03	27.8	-	-0.15
2024-12-20	FULC	4.36	27.8	-	-0.15
2024-12-23	FULC	4.68	28.2	-	-0.15
2024-12-24	FULC	4.55	28.2	-	-0.15
2024-12-26	FULC	4.84	28.2	-	-0.15
2024-12-27	FULC	4.80	28.2	-	-0.15
2024-12-30	FULC	4.68	28.2	-	-0.15
2024-12-31	FULC	4.70	28.2	-	-0.15
2025-01-02	FULC	4.85	28.2	-	-0.15
2025-01-03	FULC	5.08	28.2	-	-0.15
2025-01-06	FULC	4.94	28.2	-	-0.15
2025-01-07	FULC	4.89	28.2	-	-0.15
2025-01-08	FULC	4.48	28.2	-	-0.15
2025-01-09	FULC	4.48	28.2	-	-0.15
2025-01-10	FULC	4.37	28.2	-	-0.15
2025-01-13	FULC	4.16	28.2	-	-0.15
2025-01-14	FULC	4.06	28.2	-	-0.15
2025-01-15	FULC	4.09	28.2	-	-0.15
2025-01-16	FULC	3.98	28.2	-	-0.15
2025-01-17	FULC	3.96	28.2	-	-0.15
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	FULC	0.00	-17.31	10.09
2024-12-20	FULC	0.00	-17.31	10.09
2024-12-23	FULC	0.00	-17.35	10.09
2024-12-24	FULC	0.00	-17.35	10.09
2024-12-26	FULC	0.00	-17.35	9.36
2024-12-27	FULC	0.00	-17.35	9.36
2024-12-30	FULC	0.00	-17.93	9.36
2024-12-31	FULC	0.00	-17.93	9.36
2025-01-02	FULC	0.00	-17.93	9.36
2025-01-03	FULC	0.00	-17.93	9.36
2025-01-06	FULC	0.00	-17.86	9.36
2025-01-07	FULC	0.00	-17.86	9.36
2025-01-08	FULC	0.00	-17.86	9.36
2025-01-09	FULC	0.00	-17.86	9.36
2025-01-10	FULC	0.00	-17.86	9.36
2025-01-13	FULC	0.00	-9.81	9.31
2025-01-14	FULC	0.00	-9.81	9.31
2025-01-15	FULC	0.00	-9.81	9.31
2025-01-16	FULC	0.00	-9.81	9.31
2025-01-17	FULC	0.00	-9.81	9.31
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.35

Avg. EPS Est. Current Quarter

-0.29

Avg. EPS Est. Next Quarter

-0.26

Insider Transactions

Institutional Transactions

-9.81

Beta

2.05

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-92.7

Target Price

5.67

P/E

Forward P/E

PEG

P/S

2.64

P/B

0.83

P/Free Cash Flow

EPS

-0.31

Average EPS Est. Cur. Y

-0.15

EPS Next Y. (Est.)

-1.05

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-22.15

Relative Volume

0.52

Return on Equity vs Sector %

-26

Return on Equity vs Industry %

-13.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.09

EBIT Estimation

Fulcrum Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 76

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. It has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

stock quote shares FULC – Fulcrum Therapeutics Inc Stock Price stock today

news today FULC – Fulcrum Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch FULC – Fulcrum Therapeutics Inc yahoo finance google finance

stock history FULC – Fulcrum Therapeutics Inc invest stock market

stock prices FULC premarket after hours

ticker FULC fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: FULC

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y